Precision Biosciences hopes it can be the first to bring an allogeneic CAR-T to market, and prove the value of its gene-editing platform. • Source: Alamy
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
